72 related articles for article (PubMed ID: 26475285)
1. Treating Osteoporosis with Denosumab in Patients on Hemodialysis: The Good, the Bad, and the Ugly.
Nickolas TL
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1116-1118. PubMed ID: 37533153
[No Abstract] [Full Text] [Related]
2. Denosumab in the treatment of osteoporosis associated with chronic kidney disease.
Covic A; Apetrii M
Lancet Diabetes Endocrinol; 2024 Apr; 12(4):225-227. PubMed ID: 38373426
[No Abstract] [Full Text] [Related]
3. Adherence in the pharmacological treatment of osteoporosis.
Carbonell-Abella C; Torguet Carbonell J; Martínez Martí M
Med Clin (Barc); 2024 Jun; 162(11):e59-e63. PubMed ID: 38614904
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.
Arase Y; Tsuruya K; Hirose S; Ogiwara N; Yokota M; Anzai K; Deguchi R; Shiraishi K; Shirai T; Kagawa T
Hepatology; 2020 Feb; 71(2):757-759. PubMed ID: 31429969
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.
de Castro LF; Michel Z; Pan K; Taylor J; Szymczuk V; Paravastu S; Saboury B; Papadakis GZ; Li X; Milligan K; Boyce B; Paul SM; Collins MT; Boyce AM
N Engl J Med; 2023 Feb; 388(8):766-768. PubMed ID: 36812441
[No Abstract] [Full Text] [Related]
6. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.
Khan A; Morrison A; Cheung A; Hashem W; Compston J
Osteoporos Int; 2016 Mar; 27(3):853-859. PubMed ID: 26493811
[TBL] [Abstract][Full Text] [Related]
8. Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
Support Care Cancer; 2016 Jan; 24(1):457-458. PubMed ID: 26482379
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Dellis A; Papatsoris A
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):5-10. PubMed ID: 26588857
[TBL] [Abstract][Full Text] [Related]
10. Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence.
Cairoli E; Eller-Vainicher C; Chiodini I
Int J Womens Health; 2015; 7():833-9. PubMed ID: 26508890
[TBL] [Abstract][Full Text] [Related]
11. Osteocytic signalling pathways as therapeutic targets for bone fragility.
Plotkin LI; Bellido T
Nat Rev Endocrinol; 2016 Oct; 12(10):593-605. PubMed ID: 27230951
[TBL] [Abstract][Full Text] [Related]
12. Denosumab after 8 years.
Reid IR
Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
[No Abstract] [Full Text] [Related]
13. Cancel the denosumab holiday.
McClung MR
Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
[No Abstract] [Full Text] [Related]
14. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
15. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
16. How Long to Treat with Denosumab.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2015 Dec; 13(6):415-20. PubMed ID: 26474564
[TBL] [Abstract][Full Text] [Related]
17. Effects and management of denosumab discontinuation.
Chapurlat R
Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
